Argenx.
company in Ghent, Belgium
- Reports this week
- 0
- Active events
- 0
- Connections
- 49
What's happening
Earlier this month
One to three months ago
-
Wells Fargo and UBS analysts issued bullish predictions regarding Argenx's share price on September 20, 2026.Some support2 reports
-
Several biotech companies reported clinical trial setbacks, including Argenx and Immunovant, while Sling Therapeutics' drug was compared to offerings from Viridian and Amgen.Some support1 report
-
Argenx's CFO commented to Reuters regarding market status, following Vyvgart's approval for use in Japan.Some support1 report
-
Argenx's drug Vyvgart showed promise in treating various inflammatory diseases.Some support2 reports
-
UBS issued a bullish note on August 26, 2026, which drove up Argenx's stock price.Some support1 report
Gone quiet
No new reports in 90+ days-
Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.Some support2 reports1 development inside
-
Argenx announced a definitive agreement to acquire Forte Biosciences.Well supported14 reports
-
Argenx SE formed a strategic alliance with Unnatural Products Inc. and expanded its therapies across several countries.Some support2 reports
-
Investor interest in the healthcare AI sector is rising, with future viability depending on Phase 3 trial outcomes.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Argenx this week
News at the entities that move Argenx most-
UBS OperationalOnto Innovation participated in investor conferences hosted by Morgan Stanley and UBS at the New York Stock Exchange.Moves Argenx
-
Nasdaq StructuralWabtec stock joined best lists following a market growth driven by Nasdaq's performance.Moves Argenx
-
Wells Fargo Mentioned togetherWells Fargo paid fines related to SEC actions concerning misconduct uncovered by whistleblower Michael Bacon.Moves Argenx
-
Reuters TransactionalReuters reported CoreWeave's earnings figures, noting that Michael Intrator serves as the company's CEO.Moves Argenx
-
Netherlands Shared contextSupermicro participated in a conference circuit across multiple US cities, including New York, Arizona, and San Francisco, while also manufacturing in the Netherlands.Moves Argenx
-
Meta Mentioned togetherUnited Airlines banned Meta's AI agents from booking flights, citing federal rules regarding AI data access.Moves Argenx
Connections
The 15 strongest of 49, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Forte Transactional
Argenx is acquiring Forte, leading to a merger of Forte into Argenx.
-
Alexandra Roy Structural
Alexandra Roy holds the formal role of Investor Contact for Argenx.
-
Nasdaq Structural
Argenx is a publicly traded company listed on the Nasdaq exchange.
-
University of Pittsburgh Operational
The company utilizes the university for ongoing research collaboration.
-
Reuters Transactional
Argenx's CFO provided market status commentary to Reuters.
-
Rohit Aggarwal Operational
Dr Aggarwal functions as an investigator for a Phase III clinical trial associated with Argenx.
-
Unity Operational
Argenx stopped a research study involving Unity due to futility.
-
UBS Operational
UBS issues market notes and predictions that directly influence Argenx's stock price and market perception.
Show all 15 connections
-
National Geographic Operational
Argenx and National Geographic have established a partnership.
-
Goldman Sachs International Transactional
Goldman Sachs International acted as the exclusive financial adviser for Argenx regarding an acquisition.
-
Nathan Miller Operational
Nathan Miller is a client relations manager for a firm that is investigating Argenx.
-
Wells Fargo Mentioned together
Wells Fargo analysts provide market predictions and commentary regarding Argenx's share price.
-
Netherlands Shared context
Argenx conducts its operations and announcements within the Netherlands.
-
Teva Pharmaceutical Industries Ltd. Operational
Both companies are actively competing in the market by developing drug prospects against celiac disease.
-
Meta Mentioned together
The single snapshot provided describes Argenx utilizing Disney's channels, not a relationship between Meta and Argenx.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
3 events- Wells Fargo and UBS analysts issued bullish predictions regarding Argenx's share price on September 20, 2026.
- Several biotech companies reported clinical trial setbacks, including Argenx and Immunovant, while Sling Therapeutics' drug was compared to offerings from Viridian and Amgen.
- Argenx's CFO commented to Reuters regarding market status, following Vyvgart's approval for use in Japan.
August 2026
2 eventsShow 2 earlier months
June 2026
3 events- Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.
- Argenx SE formed a strategic alliance with Unnatural Products Inc. and expanded its therapies across several countries.
- Investor interest in the healthcare AI sector is rising, with future viability depending on Phase 3 trial outcomes.